piperacillin + vancomycin

Piperacillin + vancomycin is a combination of two intravenous antibiotics: piperacillin, a broad-spectrum ureidopenicillin beta-lactam antibiotic, and vancomycin, a glycopeptide antibiotic. This regimen is widely used as empiric therapy for severe infections, especially in critically ill or hospitalized patients, due to its ability to cover a wide range of pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas species. - **Mechanism of Action:** - Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. - Vancomycin inhibits bacterial cell wall synthesis by binding tightly to the D-Ala-D-Ala terminus of cell wall precursor units, blocking polymerization and cross-linking of peptidoglycan. - **Clinical Usage:** This combination is first-line therapy in intensive care for suspected or confirmed severe, hospital-acquired, or nosocomial infections, particularly when both broad Gram-negative (including Pseudomonas) and MRSA coverage are required[1][5][9]. - **Nephrotoxicity:** Multiple studies and systematic reviews associate this combination with an increased risk of acute kidney injury (AKI) compared to vancomycin or piperacillin-tazobactam alone, although the degree and clinical significance are debated and may depend on patient risk factors and dosing[1][2][3][5][9]. - **Not a Fixed-Dose Combination:** There is no uniquely branded, pre-mixed product solely containing piperacillin and vancomycin; co-administration occurs using individual drug preparations.